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Complete diff  erentiation of CD8+ T cells 
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2Department of Surgery, University of Würzburg, D-97080 Würzburg, Germany
The transplanted liver elicits systemic tolerance, and the underlying mechanism may also 
account for the persistence of liver infections, such as malaria and viral hepatitis. These 
phenomena have led to the hypothesis that antigen presentation within the liver is abor-
tive, leading to T cell tolerance or apoptosis. Here we test this hypothesis in an optimized 
orthotopic liver transplantation model. In direct contradiction to this model, the liver itself 
induces full CD8+ T cell activation and differentiation. The effects of microchimerism were 
neutralized by bone marrow transplantation in the liver donor, and the lack of liver-derived 
antigen-presenting cells was documented by eight-color fl  ow cytometry and by sensitive 
functional assays. We conclude that local antigen presentation cannot explain liver tolerance. 
On the contrary, the liver may be an excellent priming site for naive CD8+ T cells.
The liver appears to have a distinctive immu-
nological role, both in terms of intrahepatic re-
sponses and in systemic immunity. Hepatotropic 
pathogens like hepatitis B, hepatitis C, and 
malaria frequently fail to be cleared by the im-
mune system and become chronic infections 
(1, 2). In contrast to skin, kidney, or heart 
transplants, allogeneic liver transplants are ac-
cepted by the recipient without immunosup-
pression in many experimental models. This 
graft acceptance usually results in donor-spe-
cifi  c tolerance, whereas other MHC-disparate 
tissues are still readily rejected (3–7). In hu-
mans, liver transplants require less immunosup-
pressive therapy and experience fewer and less 
severe T cell–mediated rejection episodes than 
other vascularized organ grafts (8). In cer-
tain cases, liver transplant recipients can be 
  completely weaned from immunosuppressive 
therapy without experiencing rejection (9). 
Tolerance induction has also been observed 
when antigen is administered via the gastroin-
testinal tract, a phenomenon known as oral tol-
erance (10). Evidence that the liver has a crucial 
role in this process is derived from direct injec-
tion of antigen or allogeneic cells into the 
  portal vein, resulting in tolerance (11, 12). 
Moreover, oral tolerance does not develop if 
the blood fl  ow from the intestine bypasses the 
liver as a result of porto-systemic shunting (13). 
Because the liver is continuously exposed to 
harmless food antigens and components of the 
commensal gut bacteria, a tolerogenic predis-
position is believed to protect the organ from 
constant infl   ammation and consequent by-
stander damage (14). Despite this bias toward 
tolerance, there are other situations in which 
hepatic infections result in a robust immune re-
sponse, clearance of the pathogen, and func-
tional memory. This is observed in almost all 
hepatitis A infections and to a variable extent in 
patients with hepatitis B and C infections (1). 
In addition, autoimmune hepatitis directed 
against hepatic antigens indicates that hepatic 
tolerance can be broken, causing self-destructive 
infl  ammation (15).
Because most of these phenomena are in 
response to intracellular pathogens or antigens, 
research activities have focused on the modula-
tion of CD8+ T cell responses by hepatic tissue. 
It has been demonstrated that two cell popula-
tions in the liver, hepatocytes and liver sinusoi-
dal endothelial cells (LSECs), can activate naive 
CD8+ cells. The LSECs are a special type of 
endothelial cell lining the hepatic sinusoids that, 
unlike regular endothelial cells, are effi   cient 
in the uptake of antigen and its presentation 
via MHC class I and II. Both in vitro culture 
  experiments and an adoptive transfer model of 
isolated LSECs indicate that antigen presentation 
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by LSECs can induce tolerance in CD8+ T cells (16). He-
patocytes have also been identifi  ed as potential tolerogenic 
APCs for naive CD8+ lymphocytes. Transgenic expression of 
allogeneic MHC class I molecules on cultured hepatocytes in-
duced rapid activation of TCR transgenic CD8+ lymphocytes 
specifi  c for the allo-MHC, followed by their premature death 
(17). However, adoptive transfer of TCR transgenic lympho-
cytes caused hepatocyte damage, suggesting that the T cells 
were fully activated (18). Recent investigations have demon-
strated that depending on the promoter used, the transgenic 
allo-MHC class I antigen was also expressed in lymphatic tis-
sue, which resulted in a productive immune response. This 
led to the hypothesis that localized antigen presentation by 
hepatocytes results in tolerance by causing premature T cell 
death, whereas antigen presentation in lymphatic tissue by 
professional APCs promotes immunity (19).
Each approach to the analysis of the immune responses to 
liver antigens carries its own burden of complicating factors. 
Isolated populations of potential liver APCs are subject to 
issues of low-level contamination by other cell types, and 
their isolation from the liver’s architecture may change their 
biological function. Even if such isolated cells are replaced in 
vivo by adoptive transfer, issues of contamination and ana-
tomical organization remain. Transgenic models of antigen 
expression circumvent these issues but may be diffi   cult to 
interpret because of the potential extrahepatic expression of 
the transgenic antigen. Experiments are further limited by the 
fact that among the potential liver APC populations, strongly 
lineage-restricted promoters are available only for the hepa-
tocyte. Finally, the continuous, constitutive expression of a 
transgenic antigen, either in the liver or at a low level in the 
thymic medulla, may elicit regulatory T cells with the poten-
tial to complicate the analysis of immune responses (20, 21).
To investigate the infl  uence of restricted intrahepatic an-
tigen presentation on all hepatic cell types, we used the novel 
approach of transplanting the whole liver and exploiting ge-
netic disparities between donor and host to test the APC func-
tion of the liver alone. This approach minimizes the role of 
regulatory cell populations because a peptide antigen may be 
introduced acutely and presented only by resident cells of the 
liver grafts. In particular, and in contrast to transgenic mod-
els driven by “liver-specifi  c” promoters, our model excludes 
occult eff  ects of antigen presentation in the thymus. To our 
surprise, restricted intrahepatic antigen presentation resulted 
in activation and proliferation of adoptively transferred CD8+ 
T cells. These T cells did not undergo early apoptosis but 
completed their diff  erentiation into cytotoxic eff  ector cells.
These experiments demonstrate that antigen presentation 
in the liver is suffi   cient to promote the activation and full dif-
ferentiation of CD8+ cells. To make sense of this result in 
terms of the evidence for CD8+ T cell tolerance induced by 
hepatocyte antigen in transgenic models (19), we argue that 
T cell tolerance in these models is not a direct consequence 
of restricted intrahepatic antigen presentation, but instead 
Figure 1.  Experimental design and histologic results of mouse 
liver transplantation. (A) Mouse liver transplantation with complete 
replacement of the recipient’s liver by a donor graft was used to limit 
antigen presentation to the liver. Livers from C57BL/6 mice were trans-
planted into bm8 mice that are unable to present SIINFEKL peptide on 
MHC class I. (B) The protocol was refi  ned to eliminate extrahepatic 
antigen presentation by graft-derived passenger leukocytes. Liver 
  donors were irradiated and reconstituted with recipient-type bone 
marrow 4 wk before transplantation. 4 wk after transplantation, trans-
genic OT-I cells were adoptively transferred into transplant recipients 
that presented the specifi  c peptide only within the transplanted livers. 
Histological sections of naive B6 control animals (C) and bm8 trans-
plant recipients of livers from radiation bone marrow chimeras (D). 
Hematoxylin and eosin staining at a magnifi  cation of 200, and inset at 
a magnifi  cation of 300 (scale bar, 100 μm). The transplanted livers 
showed no evidence of rejection.JEM VOL. 203, February 20, 2006  439
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may be due to regulatory T cells that result from the constitu-
tive expression of the antigen. Thus, these models address the 
basis of self-tolerance while the experiments here address the 
response to newly expressed liver antigens, such as those en-
coded by pathogens or neoplasms.
RESULTS
Mouse liver transplantation provides a model of acute 
hepatic antigen presentation
Several cell types in the liver are known to present antigen 
to T cells (22, 23). We achieved hepatic presentation of an-
tigen using orthotopic whole organ liver transplantation in 
mice. Although the surgery is technically challenging, the 
availability of mutant and congenic strains renders mice the 
only species in which this kind of analysis is possible. Livers 
of B6.C-H-2bm8 (bm8) mice were completely removed and 
replaced by wild-type C57BL/6 livers (for details see Ma-
terials and methods). Recipient mice expressed the Kbm8 
mutation in the Kb molecule and were therefore unable to 
present the ovalbumin-derived peptide SIINFEKL, which 
was introduced as a model antigen throughout the experi-
ments (24). The liver grafts from donor mice expressed the 
wild-type MHC class I molecule Kb and were competent 
to present the antigen. Recipient mice were allowed to re-
cover for 4 wk before additional experiments (Fig. 1 B). After 
successful surgery, mice resumed normal activity by 2 d and 
regained their initial body weight within 8 d. We excluded 
any mice with jaundice, which was usually a result of bile 
duct obstruction. Histologic evaluation of the liver grafts 
4 wk after transplantation showed no infl  ammatory cell in-
fi  ltration (Fig. 1, C and D) as well as normal liver architec-
ture without signifi  cant fi  brotic changes or alterations in the 
intrahepatic leukocyte populations as compared with naive 
bm8 control animals (Fig. S1, available at http://www.jem.
org/cgi/content/full/jem.20051775/DC1).
Liver transplantation from bone marrow chimeric donors 
eliminates antigen presentation by donor-derived 
migratory leukocytes
Despite extensive perfusion of the liver grafts with saline so-
lution before transplantation, bone marrow–derived cells of 
organ donors have been found in transplant recipients, a phe-
nomenon termed microchimerism (25, 26). Therefore, we 
next investigated the extent and phenotype of microchimeric 
donor-derived cells in liver transplant recipients. Liver grafts 
from congenic B6.SJL mice (CD45.1 background) were 
transplanted into bm8 animals (CD45.2 background). 4 wk 
after liver transplantation, spleens and peripheral lymph nodes 
of transplant recipients were harvested and analyzed by eight-
color fl   ow cytometry. Based on their expression of the 
CD45.1 congenic marker, 0.1–0.3% of all leukocytes in 
spleens (Fig. 2 A) and 0.05–0.2% of peripheral lymph node 
cells (not depicted) were of donor origin. Among these do-
nor leukocytes, 30–50% were professional APCs expressing 
Figure 2.  Microchimerism in transplant recipients of liver 
grafts from untreated B6 and [bm8→B6] radiation bone marrow 
chimeras. (A) bm8 (CD45.2) recipients of untreated B6.SJL (CD45.1) 
livers were killed 4 wk after liver transplantation. The frequency and 
phenotype of donor-  derived passenger leukocytes in spleens and pe-
ripheral lymph nodes was assessed by eight-color flow cytometry 
based on the congenic marker CD45.1. (B) Microchimerism in recipi-
ents of livers from radiation bone marrow chimeras, in which the bone 
marrow–derived cells were replaced by bone marrow of the recipient 
mouse strain (bm8) 4 wk before liver transplantation. Data are repre-
sentative of two independent experiments with three mice per group. 
Bottom: average percentage (±SEM) of donor-derived passenger 
  leukocytes as a fraction of the total number of donor-derived CD45.1+ 
cells (six animals per group). The radiation reduced microchimerism 
by 90% and abolished the transfer of professional APCs (dendritic 
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dendritic cell or B cell lineage markers. These made up 
0.03–0.14% of total leukocytes in the spleen and <0.1% in 
the peripheral lymph node compartment. Remaining lym-
phocytes were CD4+ and CD8+ T lymphocytes, NK cells, 
and NKT cells (Fig. 2 A). To minimize the possibility of ex-
trahepatic antigen presentation by donor-derived passenger 
leukocytes, we created bone marrow chimeras, in which 
B6.SJL (H-2b, CD45.1) mice were reconstituted with bone 
marrow of the liver transplant recipient strain bm8 (Fig. 1 B). 
These bone marrow chimeras were allowed to reconstitute 
for 4 wk, and then were used as donors in liver transplanta-
tion experiments. 4 wk after liver transplantation, the per-
centage of CD45.1+ cells had decreased  10-fold in spleens 
to 0.02–0.04% (Fig. 2 B). In the lymph nodes, donor-specifi  c 
cell numbers were reduced by half to 0.03–0.05% (not de-
picted). More signifi   cantly, donor-derived H-2b passenger 
leukocytes in these animals consisted almost entirely of T 
lymphocytes and NKT cells, whereas donor-derived den-
dritic cells were only detectable as a few individual events on 
a dot plot (too few to quantitate, <0.01%), and B cells of do-
nor origin were no longer detectable (Fig. 2 B).
To explicitly test whether the presentation of SIINFEKL 
antigen could be mediated by these very rare donor-derived 
APCs, we used an in vitro proliferation assay in which the 
ability of extrahepatic tissues to induce proliferation of trans-
genic OT-I T cells was evaluated. 4 wk after transplantation, 
bm8 animals grafted with a [bm8→B6] bone marrow chime-
ric liver were injected on three consecutive days with SIIN-
FEKL peptide. Leukocytes were isolated from spleens, 
peripheral and mesenteric lymph nodes, and bone marrow. 
Livers were harvested, and a whole organ cell suspension 
containing hepatocytes, endothelial cells, and nonparenchy-
mal leukocytes was prepared. Cell suspensions from all organs 
were cocultured for 3 d with CFSE-labeled transgenic OT-I 
cells, which were on a CD90.1 (Thy-1.1) background. Their 
antigen-specifi  c proliferation was assessed by fl  ow cytometry 
based on the dilution of CFSE in CD90.1+ T cells. As shown 
in Fig. 3, extensive proliferation occurred in all analyzed or-
gans in control transplant recipients, in which a B6 donor was 
irradiated and reconstituted with B6 bone marrow, and the 
liver was transplanted into a B6 recipient ([B6→B6]→B6). 
However, in bm8 recipients of B6 liver grafts that had been 
irradiated and reconstituted with bm8 bone marrow ([bm8→
B6]→bm8), proliferation of OT-I cells was observed only in 
coculture with CD45− or unfractionated cells from the liver 
grafts. This was not due to limiting antigen because the re-
sults were consistent even when SIINFEKL peptide was 
added to the cultures in a concentration of 1 μM. Therefore, 
we concluded that the transplantation of a liver from a 
[bm8→B6] donor resulted in restricted intrahepatic antigen 
presentation in recipient bm8 animals. In contrast, antigen 
presentation was systemic in control animals in which all 
components (bone marrow and parenchyma of the graft as 
well as the recipient) were of B6 origin.
Intrahepatic presentation of antigen leads to proliferation 
of naive CD8+ T cells
We tested whether the restricted presentation of antigen 
within the liver in our model would be suffi   cient for the ac-
tivation of naive CD8+ T cells. We adoptively transferred 
TCR transgenic OT-I cells into transplant recipients. To en-
sure a naive phenotype, transgenic OT-I cells were FACS 
sorted selecting for the CD44low CD62Lhigh cell population 
(Fig. 4 A). After SIINFEKL injection for three consecutive 
days, control transplant recipients with systemic Kb antigen 
presentation showed expansion of antigen-specifi  c OTI cells 
in livers, spleens, and peripheral lymph nodes (Fig. 4 B). In 
animals with restricted hepatic Kb antigen presentation, OT-I 
expansion was similar or even exceeded the expansion seen 
in animals with systemic Kb antigen presentation. Expansion 
did not occur in the absence of specific antigen (Fig. 4 B, 
hepatic Kb PBS control).
To evaluate whether the similar percentages of OT-I cells 
in the liver and lymphatic organs of both groups were a result 
of equally expanding populations or simply a refl  ection of a 
Figure 3.  Organ-specifi  c detection of antigen presentation by 
ex vivo T cell proliferation assay. Antigen presentation in spleens, pe-
ripheral and mesenteric lymph nodes, bone marrow, and livers (unfrac-
tionated and fractionated into CD45+ and CD45− cells) was assessed 
independently using an in vitro T cell proliferation assay 4 wk after trans-
plantation. bm8 recipients of liver transplants from [bm8→B6] bone mar-
row chimeras (hepatic kb expression, open graphs) were compared with 
B6 recipients of liver grafts from [B6→B6] bone marrow chimeras (sys-
temic kb expression, fi  lled graphs). 4 wk after transplantation, transplant 
recipients were injected with SIINFEKL peptide, and then cell suspensions 
from spleens, peripheral and mesenteric lymph nodes, bone marrow, and 
livers were cocultured with CFSE-stained OT-I cells (CD90.1 background). 
Organ-specifi  c antigen presentation was determined by dilution of CFSE 
in OT-I cells. The histograms show OT-I T cells based on their expression of 
CD90.1. These data demonstrate that the capacity to present the SIINFEKL 
peptide in the hepatic kb expression group was exclusive to the CD45− 
and unfractionated intrahepatic cells of the transplanted livers. Data are 
representative of three independent experiments with two mice per 
group, and fractionation of liver cells based on CD45 expression was 
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disproportionate cell distribution, we transferred CFSE-
stained OT-I cells and evaluated proliferation and cell divi-
sion by dilution of CFSE. By day 4 after the fi  rst antigen 
encounter, cytoplasmic CFSE staining in both groups was 
completely diluted, indicating more than six cell divisions 
(Fig. 5). There was also no detectable diff  erence in CFSE di-
lution between both groups earlier on day 2 (not depicted). 
In the absence of antigen, no CFSE dilution was observed 
(Fig. 5). During the early phase of the immune response, 
OT-I T cells in the hepatic Kb antigen presentation group 
were found in the spleens and lymph nodes of these animals, 
indicating that they recirculated after intrahepatic antigen 
 encounter. The proliferative response peaked on day 4 after 
either systemic or hepatic antigen presentation, followed by a 
contraction phase. However, OT-I cell numbers decreased 
more gradually in animals with restricted hepatic Kb presen-
tation as compared with the control group with systemic Kb 
presentation (Fig. 5).
Activation of TCR transgenic OT-I cells was similar in 
both groups, based on the surface expression of activation 
markers. Up-regulation of CD44 expression on OT-1 T cells 
was observed in the livers, spleens, and lymph nodes of mice 
with either systemic or exclusively hepatic antigen presenta-
tion (Fig. 5). Similarly, there was equivalent and synchronous 
down-regulation of CD62L on the OT-1 T cells in both 
groups of liver-transplanted hosts (not depicted).
CD8+ T cells acquire full effector functions when primed 
in the liver
Because naive CD8+ T cells responded to intrahepatic anti-
gen presentation by activation and proliferation, we were in-
terested in the functional potential of these cells. OT-I cells 
from liver grafts, spleens, and lymph nodes were iso-
lated on days 2 and 4 after antigen encounter, and their 
ability to produce IFN-γ was tested by intracellular cytokine 
staining after a 6-h restimulation period. Restricted hepatic 
antigen presentation had no negative eff  ect on IFN-γ pro-
duction, which was the same as that observed in mice with 
Figure 4.  In vivo expansion of naive OT-I T cells after hepatic and 
systemic antigen presentation. Naive OT-I cells for adoptive transfer 
were obtained by magnetic bead depletion, followed by FACS sorting for 
transgenic T cells with a naive phenotype. (A) Purity and activation status 
of adoptively transferred OT-I T cells before and after fl  ow cytometric cell 
sorting. (B) Expansion of adoptively transferred OT-I T cells detected in 
livers, spleens, and peripheral lymph nodes of transplant recipients. For 
restricted hepatic kb antigen presentation, livers from [bm8→B6] bone 
marrow chimeras were transplanted into bm8 recipients. Systemic kb anti-
gen presentation was achieved by transplanting livers from [B6→B6] 
bone marrow chimeras into B6 recipients. 4 wk after transplantation, 5 × 
106 naive OT-I cells (CD90.1 background) were adoptively transferred and 
the animals received three i.p. injections of either SIINFEKL peptide or PBS 
(hepatic kb PBS control). 4 d after the initial antigen contact, transplant 
recipients were killed and the number of OT-I cells was assessed by fl  ow 
cytometry. Data are representative of three independent experiments with 
three mice per group, and sorted and unsorted OT-I cells were used for 
adoptive transfer without signifi  cant differences in the extent of prolif-
eration. This shows that antigen presentation in the transplanted liver can 
cause extensive clonal expansion.
Figure 5.  Kinetics and activation status of intrahepatically acti-
vated OT-I T cells. Left column: Absolute cell numbers of adoptively 
transferred OT-I T cells 2, 4, and 6 d after initial SIINFEKL injection. Trans-
plant recipients with hepatic or systemic capability to present antigen 
 received  5  × 106 OT-I T cells and were injected with SIINFEKL or PBS (he-
patic kb PBS control) on days 0, 1, and 2. OT-I cell numbers from livers, 
spleens, and peripheral lymph nodes were calculated based on fl  ow cy-
tometry data and organ cell counts. Right column: Proliferation and acti-
vation status of OT-T cells in animals with hepatic and systemic kb antigen 
presentation demonstrated by dilution of CFSE staining and expression of 
CD44 on day 4 after initial antigen or PBS injection. The data show that 
CD8+ T cell activation in the liver causes massive proliferation and seeding 
of the lymphoid organs. The data are representative of three independent 
experiments with three mice per group, and error bars indicate SEM.442  COMPLETE MATURATION OF LIVER-PRIMED CD8 T CELLS | Klein et al. 
systemic presentation (Fig. 6 A). In the absence of antigen re-
stimulation (media without added SIINFEKL peptide), no 
signifi  cant cytokine production was detectable at the end of 
the culture period. OT-I cells that were primed within liver 
grafts readily produced IFN-γ upon restimulation, as early as 
2 d after antigen contact. During the course of the immune 
response, IFN-γ–producing OT-I cells initially recirculated 
into peripheral lymphatic organs and later accumulated in the 
livers of both groups, resulting in a higher percentage com-
pared with spleens and lymph nodes on day 4 of the immune 
response (Fig. 4 B). Despite this higher percentage in the 
liver, the fraction of OT-I cells that responded to peptide re-
stimulation by IFN-γ production was not signifi  cantly diff  er-
ent between the liver and the lymphatic organs (Fig. 6 B; 
liver, P = 0.77; spleen, P = 0.52; lymph nodes, P = 0.71). 
This indicates that the liver environment does not negatively 
infl  uence the ability of CD8+ T cells to produce IFN-γ. In 
PBS-injected transplant recipients, no cytokine production 
was observed 6 h after restimulation. Also, the percentage of 
cytokine-producing OT-I cells as well as the total OT-I cell 
number in transplanted animals was similar to that observed 
in nontransplanted B6 mice after OT-I transfer and peptide 
injection. This indicated that the transplantation technique 
did not aff  ect the quality of the immune response as deter-
mined by cytokine production (not depicted).
The hallmark of CD8+ T cell eff  ector function is cytotoxic 
activity. Therefore, we investigated the cytotoxic potential of 
intrahepatically activated CD8+ T cells using an in vivo cyto-
toxicity assay. Wild-type B6 splenocytes were pulsed with the 
SIINFEKL peptide and stained with a high CFSE concentra-
tion. These specifi  c target cells were mixed in a 1:1 ratio with 
nonspecifi  c target cells, which were pulsed with the infl  uenza 
PA peptide and stained with a lower CFSE concentration 
(Fig. 7 A). On days 5 and 6 of the immune response, transplant 
recipients were injected with the 1:1 mixture of specifi  c and 
nonspecifi  c targets. 4 h later, livers, spleens, and lymph nodes 
were harvested and analyzed for CFSE+ cells (Fig. 7 A). Cyto-
toxicity was defi  ned by the reduction of SIINFEKL-pulsed 
specifi  c targets (CFSEhigh) compared with nonspecifi  c target 
cells (CFSElow) as shown in Fig. 7, B and C. Antigen-spe-
cifi  c disappearance of SIINFEKL-pulsed splenocytes provided 
evidence of antigen-specifi  c cytotoxicity and was observed in 
both groups of liver-transplanted mice. There was no clear 
diff  erence in the priming of cytotoxic function between sys-
temic and hepatic CD8+ T cell activation (liver, P = 0.2; 
spleen, P = 0.5; lymph nodes, P = 0.21). In control animals in 
which OT-I cells had not been activated by their specifi  c pep-
tide (hepatic Kb PBS control), the ratio of specifi  c versus non-
specifi  c target cells remained unchanged from the preinjection 
ratio. Cytotoxicity was not mediated by an endogenous SIIN-
FEKL-specifi  c cell population; transplant recipients that had 
not received OT-I cells but were injected with the SIINFEKL 
peptide for 3 d showed no disappearance of specifi  c target cells 
(Fig. 7 B). Compared with systemic priming, hepatic Kb pre-
sentation resulted in slightly greater specifi  c killing, especially 
in livers and lymph nodes. However, this increased killing was 
more likely due to higher OT-I cell numbers during the late 
phase of the immune response rather than a diff  erence in cyto-
toxicity on a single cell level (Fig. 5).
DISCUSSION
Several aspects of hepatic biology demonstrate that immune 
responses tend to be skewed toward immunological tolerance 
in the liver. Several mechanisms have been identifi  ed that are 
orchestrated to cause this phenomenon. Hepatic dendritic 
cells with an immature phenotype have been shown to mi-
grate to lymphatic organs and exert tolerogenic functions 
(27). Activated CD8+ lymphocytes are eff  ectively trapped in 
the liver and eliminated from the circulating blood by in-
duction of apoptosis (28, 29). Although these mechanisms 
may contribute to the regulation of systemic immune re-
sponses, the initiation of immune responses in the liver itself 
may also result in immunological tolerance, as seen in oral 
tolerance and other models. Recent studies comparing mouse 
models with transgenic intrahepatic plus or minus extrahe-
patic antigen expression have concluded that although initial 
presentation of antigen in lymphatic organs results in immu-
nogenic responses, antigen presentation in the liver promotes 
tolerance induction of specifi  c CD8+ T cells (19).
Figure 6.  IFN-𝗄 production of OT-I T cells after restimulation with 
cognate antigen. (A) Liver transplant recipients with restricted intrahe-
patic or systemic antigen presentation were killed on day 4 after initial 
antigen injection. Cell isolates from livers, spleens, and lymph nodes were 
restimulated with SIINFEKL peptide for 6 h and their IFN-γ production 
was assessed by intracellular cytokine staining. (B) Average percentage of 
IFN-γ producers among isolated OT-I T cells. These experiments show that 
priming in liver produces fully functional CD8+ T cells. Data are represen-
tative of three independent experiments with three mice per group, and 
the bars in B represent the mean ± SEM.JEM VOL. 203, February 20, 2006  443
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In this work, this hypothesis was tested using a novel 
  approach. Antigen was acutely introduced and its presenta-
tion was restricted to resident cells of a previously transplanted 
liver graft. Surprisingly, local intrahepatic antigen presenta-
tion in our model was suffi   cient for the full activation and 
diff  erentiation of naive CD8+ T cells without the need for 
initial priming in lymphatic organs.
It is generally agreed that CD4+ T cell responses are de-
pendent on antigen presentation and costimulatory signals of 
mature dendritic cells within regional lymph nodes, and that 
priming does not occur outside lymphatic organs (30). In the 
case of initial priming of CD8+ lymphocytes, the absolute 
need for costimulation is less well established. Full activation 
and diff  erentiation was observed in CD28-defi  cient mice that 
were infected with lymphocytic choriomeningitis virus (31), 
and the T cell–mediated destruction of pancreatic β cells 
was unaff  ected in CD28-defi  cient nonobese diabetic mice 
(32). In vitro, full activation and diff  erentiation of transgenic 
CD8+ T cells has been induced by peptide-loaded tetramers, 
despite the lack of costimulation (33). From these studies it 
would be predicted that the special costimulatory properties 
of dendritic cells are optional for CD8+ T cells. The current 
work, in which we show that priming and full activation of 
naive CD8+ T cells can occur independent of lymphatic or-
gans, is consistent with this view of CD8+ T cell priming. 
The complete, acute activation and diff  erentiation of naive 
CD8+ T cells was demonstrated by specifi  c cytotoxicity 
until day 6 after initial peptide activation. This argues against 
a defective initial activation of naive CD8 T+ cells as the 
exclusive reason of liver-mediated CD8+ T cell tolerance. 
Because this experimental model depends on the intrahe-
patic expression of an MHC class I restriction element, and 
the antigen is a class I–restricted peptide, the model ex-
cludes the participation of CD4+ T helper cells, which have 
been shown to be essential for the long-term survival of 
memory cells. Without help, memory CD8+ T cell survival 
is impaired; therefore, we do not draw the conclusion that 
the fully activated CD8+ T cells would be likely to diff  eren-
tiate into memory cells.
In the context of the liver transplantation model, it is 
appropriate to consider whether the observed CD8+ T cell 
activation could be occurring in neo-lymphatic tissue, in-
duced in the liver grafts by chronic infl  ammation, due to 
low-grade rejection. Liver transplants in mice are generally 
accepted by the recipient without the need for immuno-
suppression and result in donor-specifi  c tolerance (34). In 
our model, stable graft acceptance and tolerance induction 
toward the B6 liver parenchyma was observed by 4 wk after 
liver transplantation. Adoptive transfer of B6 lymphocytes, 
either in the form of OT-I cells in the proliferation experi-
ments or as B6 splenocytes in the in vivo cytotoxicity as-
says, were accepted without rejection, consistent with the 
induction of full transplantation tolerance in the fi  rst 4 wk 
after transplantation of the chimeric liver graft. In contrast to 
this, adoptive transfer of B6 cells into either nontransplanted 
bm8 mice as well as bm8 recipients of [bm8→bm8] bone 
marrow chimeric livers resulted in rejection and complete 
disappearance of these cells within the fi  rst 2 d after transfer 
(not depicted). However, there was no histological evidence 
of lymphocyte infi  ltration or chronic rejection detectable in the 
liver transplants 4 wk after transplantation (Fig. 1 and Fig. S1). 
Other potential causes of liver infl  ammation, such as infec-
tion with pathogens (in particular mouse hepatitis virus), 
were not observed in our mouse colonies for the entire time 
of the experiments.
Figure 7.  In vivo CTL challenge with SIINFEKL-pulsed target cells. 
(A) OT-I cells were adoptively transferred into transplant recipients with 
restricted hepatic or systemic kb antigen presentation and primed by SIIN-
FEKL injection. 5–6 d after initial antigen encounter, mice were tested for 
cytotoxic T cells by injection of SIINFEKL-pulsed target cells. Splenocytes 
from naive B6 animals, stained in a 2-μM CFSE solution (CFSEhigh) and 
pulsed in a 1-μM SIINFEKL solution, were used as specifi  c target cells. 
Nonspecifi  c control targets were stained in a 0.2-μM CFSE solution 
 (CFSElow) and pulsed with the infl  uenza PA peptide. Specifi  c and nonspe-
cifi  c target cells were mixed in a 1:1 ratio, and a total of 2 × 107 cells was 
injected i.v. into transplant recipients (A, preinjection). 4 h after the injec-
tion of target cells, transplant recipients were killed and cell suspensions 
from livers, spleens, and peripheral lymph nodes were analyzed for CFSE+ 
cells by fl  ow cytometry (A, right). (B) Cytotoxicity was determined by the 
increased ratio of specifi  c versus nonspecifi  c target cells (see Results and 
Materials and methods for details). Cytotoxic activity of endogenous SIIN-
FEKL-specifi  c cells was excluded in transplant recipients by three injec-
tions of cognate antigen in the absence of previous adoptive OT-I transfer 
(endogenous SIINFEKL control). (C) Percentage of specifi  c cytotoxicity in 
transplant recipients. These experiments show that antigen presented in 
the transplanted liver can prime CTLs. Data are representative of three 
independent experiments with three mice per group, and the bars in 
C represent the average ± SEM.444  COMPLETE MATURATION OF LIVER-PRIMED CD8 T CELLS | Klein et al. 
Transplantation of whole organs is accompanied by the 
transfer of passenger leukocytes from the organ donor. These 
donor-derived cells migrate out of the transplant into the re-
cipient and relocate to lymphoid and nonlymphoid organs, a 
phenomenon known as microchimerism (35, 36). Conse-
quently, in our model, passenger leukocytes in transplant re-
cipients were a potential source of antigen presentation 
outside the liver graft. To address this concern, we trans-
planted the livers from radiation bone marrow chimeras, in 
which the bone marrow–derived cells were replaced by bone 
marrow of the recipient mouse strain 4 wk before liver trans-
plantation (Fig. 1 B). This resulted in the complete disappear-
ance of the donor-derived APCs from the recipient’s spleens, 
peripheral lymph nodes, and liver grafts as detected by fl  ow 
cytometry (Fig. 2 and Fig. S2, available at http://www.jem.
org/cgi/content/full/jem.20051775/DC1). To confi  rm the 
restriction of antigen presentation to the liver grafts in a sensi-
tive functional assay, we separated hepatic antigen presenta-
tion from lymphatic antigen presentation in an ex vivo T cell 
proliferation experiment. Constituent cells from livers, pe-
ripheral and mesenteric lymph nodes, spleens, and bone mar-
row were evaluated independently for their ability to activate 
antigen-specifi  c T cells and promote their proliferation. 
  Indeed, this demonstrated that by using bone marrow chi-
meras as liver donors, microchimerism of eff  ective APCs was 
eliminated and antigen presentation was restricted to non-
bone marrow–derived cells of the liver itself (Fig. 3).
However, the immune response in vivo was not restricted 
to the transplanted organ. Instead, OT-I T cells recirculated 
systemically and were found in lymphatic tissues of the recip-
ient early in the immune response. At various time points 
during the immune response, OT-I cells isolated from spleens, 
lymph nodes, and livers showed a similar activated phenotype 
and proliferation status, and resembled each other in their 
ability to produce IFN-γ upon restimulation. This suggests 
constant recirculation between the antigen expressing liver 
and the lymphatic tissues during the ongoing immune 
  response. The actual site of expansion was not addressed by 
our experiments, and it is quite conceivable that mitotic cell 
divisions and/or T cell maturation of OT-I cells took place 
in lymphatic tissues as well as in the liver. However, the acti-
vation and proliferation of CD8+ T cells in our model was 
clearly initiated by antigen presentation in the liver. Surpris-
ingly, there was no signifi  cant diff  erence in the magnitude of 
T cell expansion when antigen was presented systemically or 
restricted to the liver. Our data indicate that the capacity of 
the liver to present antigen is suffi   cient to promote activation 
and proliferation of a large number of T cells. Several physio-
logic aspects of the liver contribute to this. The hepatic envi-
ronment, unlike that of other parenchymal organs, promotes 
the interaction of naive lymphocytes with potential tissue 
APCs. The liver is perfused by 25% of the cardiac output, 
which results in constant exposure of circulating T cells with 
presented antigen. A unique combination of narrow hepatic 
sinuses with a fenestrated endothelium and a lack of basement 
membrane, together with a low velocity blood fl  ow, allow 
perpetual contact of circulating lymphocytes with potential 
APCs in the sinusoids and the subendothelial space of Disse 
(12, 14). In addition, exposure to endotoxins and other bac-
terial products derived from the intestine provide a constant 
source of “endogenous” immunological stimulation that re-
sults in up-regulation of adhesion molecules on Kupff  er cells 
and LSECs (37).
T cell activation in this special environment has been 
shown previously. However, the fi  nal result of hepatic T cell 
activation was often premature activation-induced cell death, 
defective activation and tolerance induction in CD8+ T cells, 
or the formation of a regulatory cell type in CD4+ T cells 
(17, 38). These observations led to the hypothesis that im-
munological tolerance might be established in the liver by 
local antigen presentation and implicated a special role in this 
process for two intrahepatic cell types: the LSECs and the 
hepatocytes (38, 39).
Antigen presentation by isolated LSECs skews CD4+ T 
cell activation toward a regulatory phenotype with the ex-
pression of IL-4 and IL-10 (40). Priming of CD8+ T cells by 
LSECs resulted in incomplete activation with loss of IFN-γ 
and IL-2 cytokine production and a lack of cytotoxic activ-
ity. However, the exclusive role of LSECs in T cell priming 
has recently been questioned on the basis of experiments 
  using LSECs that were isolated based on surface marker ex-
pression rather than counterfl  ow elutriation. The problem is 
to determine whether low-level contamination of LSEC 
preparation by other APCs might have complicated the in-
terpretation of previous results (41). Whether LSECs are 
  fi  nally agreed to be self-suffi   cient APCs does not impact 
directly on our present work, but would change the proba-
bility that they, rather than hepatocytes, are the important 
local intrahepatic APC.
Incomplete activation of CD8+ T cells with a lack of 
  cytotoxicity and premature T cell death within the fi  rst few 
days after T cell priming has also been reported when trans-
genic antigen was expressed on hepatocytes (acting as non-
professional APCs). However, continuous expression of a 
transgenic antigen is known to induce regulatory T cells, cre-
ating an alternative mechanism of tolerance. Similarly, the 
promiscuous gene expression of tissue-specifi  c self-antigens 
in medullary thymic epithelial cells results in systemic central 
tolerance and formation of tolerogenic regulatory T cells 
(42–44). Therefore, modulation of CD8+ T cell responses by 
transgenic hepatic antigen could simulate mechanisms of self-
tolerance and the control of autoimmunity rather than im-
mune failure to an exogenous pathogen. In this work, antigen 
expression was introduced acutely by peptide injection, 
which would not be expected to induce thymic, self-specifi  c 
regulatory T cell populations.
Our fi  ndings support a model in which a productive im-
mune response is initially provoked by acute presentation of 
antigen within the liver, as seen in hepatic infections. In cases 
of antigen persistence, this immune response is modulated by 
regulatory systems over time, which might ultimately result 
in tolerance. This is refl  ected by the initial immune response JEM VOL. 203, February 20, 2006  445
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in viral hepatitis infections preceding the chronic stage (45) 
or the immediate phase after liver transplantation with the 
occurrence of alloreactive lymphocytes before tolerance is 
established (7). The mechanisms through which such toler-
ance is established are still poorly understood. However, in 
this work we have tested and rigorously excluded the possi-
bility that local, intrahepatic presentation of antigen to CD8+ 
T cells results in abortive interaction, maturation failure, and 
premature death. The reality is quite diff  erent. The interac-
tion of CD8+ T cells with the liver results in the proliferation 
and maturation of CTLs with full eff  ector function.
MATERIALS AND METHODS
Mice. Wild-type C57BL/6J and B6.SJL-Ptprca (B6.CD45.1) mice were 
purchased from The Jackson Laboratory. The bm8 mice were provided by 
L.R. Pease (Mayo Clinic, Rochester, MN). A colony of OT-I transgenic 
mice was maintained on a CD90.1 (Thy1.1) background. All mice were 
bred and housed in a specifi  c pathogen-free environment and used between 
6 to 10 wk of age. Experiments were performed in accordance with regula-
tory guidelines and standards set by the University Committee on Animal 
Resources of the University of Rochester.
Mouse liver transplantation. Orthotopic mouse liver transplantation, ini-
tially reported by Qian et al. (46), was performed according to a technique 
described by Steger et al. (47) in the non-rearterialized version. The donor 
liver was obtained by dissection of the surrounding hepatic ligaments; the 
right adrenal vein, pyloric vein, and proper hepatic artery were ligated and 
divided. For continuous bile fl  ow the gallbladder was ligated and removed. 
A polyethylene stent tube (inner diameter, 0.28 mm; SIMS Portex) was in-
serted into the lumen of the common bile duct and secured with 8–0 silk 
(Pearsalls). The infrahepatic inferior vena cava (IVC) and portal vein were 
clamped, and the organ was perfused with 10 ml of 4°C normal saline 
through the portal vein. The liver was removed and stored in 4°C PBS solu-
tion until transplantation. The transplantation procedure was performed un-
der inhalation anesthesia with isofl  urane. After clamping of the infrahepatic 
and suprahepatic IVC and the portal vein, the recipient’s liver was com-
pletely removed and the donor organ was placed orthotopically into the ab-
dominal cavity. The suprahepatic and the infrahepatic IVC were anastomosed 
with continuous running sutures using 10–0 nylon (Ethicon), and the portal 
vein was reconnected by cuff   anastomosis. Reconstruction of the bile fl  ow 
was achieved by inserting the graft’s stent tube into the recipient’s bile duct 
and securing it with three single 10–0 nylon sutures.
Radiation bone marrow chimera. 6–8-wk-old recipient mice were irra-
diated with a dose of 10 Gy (1,000 rad) using an RS2000 X-ray irradiator 
(RadSource Technologies). Depletion of mature T lymphocytes from donor 
bone marrow cells was achieved by incubation with anti-CD4 mAb (clone 
RL172.4) and anti-CD8 mAb (clone 3-16.8) and subsequent lysis using 
Guinea pig complement (Invitrogen). Recipient mice were injected with 
107 cells via the tail vein and were allowed to reconstitute for 28 d until 
  additional experiments.
Cell isolation procedures. For single cell suspensions, peripheral lymph 
nodes and spleens were mechanically homogenized between frosted glass 
slides. Liver leukocytes were isolated as described previously (48). In brief, 
livers were perfused with PBS, mashed through a cell strainer, and incubated 
for 40 min at 37°C in RPMI digestion buff  er containing 0.05% collagenase 
IV and 0.002% DNase I (Sigma-Aldrich). The leukocyte population was 
obtained by density gradient centrifugation using a 22% Opti-prep (Axis-
Shield) solution.
Flow cytometry and statistical analysis. Cell solutions were stained for 
20 min at 4°C with mAbs specifi  c for TCR-β, CD90.1, CD44, I-Ab, CD4, 
CD19, and IFN-γ (all from BD Biosciences); F4/80, CD8, and CD11b (all 
from Caltag Laboratories); and CD45.1, CD45.2, CD62L, and CD11c (all 
from eBioscience). For intracellular cytokine staining, the Cytofi  x/Cyto-
perm kit (BD Biosciences) was used according to the manufacturer’s instruc-
tions after restimulation in the presence or absence of 1 μM SIINFEKL 
peptide for 6 h. Ungated cell samples of the described organs were acquired 
using a BD LSR II fl  ow cytometer (BD Biosciences) and analyzed by FlowJo 
software (Tree Star) based on a lymphocyte size gate.
Adoptive transfer of OT-I cells and in vivo activation. Transgenic 
CD8+ cells from spleens and lymph nodes were enriched by magnetic deple-
tion of B cells, CD4+ T cells, dendritic cells, and NK cells using primary an-
tibody (clone 212.Al specifi  c for MHC class II molecules, clone GK1.5 
specifi  c for CD4, clone 2.4.G2 specifi  c for FcRs, and clone HB.191 specifi  c 
for NK1.1), followed by magnetic beads coated with secondary antibodies 
(QIAGEN). The purity of enriched CD8+ OT-I cells was >93% (±4%). 
To obtain a naive OT-I population, cells were sorted for a CD44low 
CD62Lhigh phenotype using a FACSAria cell sorting system (BD Biosciences). 
The purity of CD8+ OT-I cells with a naive phenotype was 99% after sort-
ing. 5 × 106 OT-I cells were injected i.v. into transplant recipients and acti-
vated by daily i.p. injections of 25 nmol SIINFEKL peptide (New England 
Peptide) for 3 d starting 12 h after injection of OT-I cells.
In vitro proliferation assay. Transplant recipients were injected i.p. for 
three consecutive days with 25 nmol SIINFEKL peptide. Cells from spleens 
and lymph nodes (cervical, axillary, brachial, inguinal, mesenteric, and celiac 
lymph nodes) were isolated by mechanical disruption. Bone marrow cells 
were obtained from femora and tibiae. Livers were perfused with a 37°C PBS 
solution containing 5% collagenase IV for 8–10 min, disrupted, and shaken to 
liberate intrahepatic cells into the media. To obtain an unbiased representa-
tion of all types of intrahepatic cells, the cell suspensions were simply washed, 
fi  ltered to remove aggregates, and used in the assay without any further 
  separation steps. To further diff  erentiate APCs in the assay we fraction-
ated such  liver cells based on their CD45 expression by fl  uorescence-
activated cell sorting using a FACSAria system (BD Biosciences). 3 × 105 cells 
from spleens, lymph nodes, and bone marrow, as well as 2 × 104   unseparated 
liver cells and 3 × 105 fractionated liver cells were resuspended in culture 
media (DMEM/F12, 10% FBS, insulin-transferrin-selenium/ITS, and peni-
cillin-streptomycin) and cocultured with 3 × 105 CFSE-stained OT-I cells. 
Cultures were maintained for 96 h before fl  ow cytometric analysis.
In vivo cytotoxicity assay. Splenocytes from C57BL/6J mice were sepa-
rated from the RBCs by density gradient centrifugation (Lympholyte-M; 
Cedarlane Laboratories), divided into two equal portions, and stained in a 
2-or 0.2-μM CFSE solution (Invitrogen), respectively. Cell suspensions 
were pulsed for 1 h with either a 1-μM solution of SIINFEKL peptide as a 
specifi  c target cell population (2 μM CFSE-stained cells) or a 1-μM solution 
of PA peptide as a control population (0.2 μM CFSE-stained cells). Specifi  c 
target cells and control population were counted and mixed in a 1:1 ratio, 
and a total of 2 × 107 cells was injected i.v. into transplant recipients. After 
5 h, spleens, lymph nodes, and livers were harvested from recipient mice and 
analyzed by fl  ow cytometry to determine the ratio of specifi  c target cells 
versus control cells. Specifi  c killing was calculated by the following formula: 
100 − ([(percentage of SIINFEKL pulsed in immunized/percentage of PA 
pulsed in immunized)/(percentage of SIINFEKL pulsed in uninmmunized/
percentage of PA pulsed in uninmmunized)] × 100).
Statistical analysis. The statistical signifi  cance of the diff  erences between 
groups of mice was tested using Student’s t test. A value of P < 0.05 was 
considered signifi  cant.
Online supplemental material. Fig. S1 depicts hepatic micro architecture 
and intrahepatic cell populations in transplanted and naive animals. Fig. S2 
shows the fraction and subpopulations of radioresistant intrahepatic kb+ 
wild-type leukocytes. Figs. S1 and S2 are available at http://www.jem.
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